Safety and feasibility study of holmium laser enucleation of the prostate (HOLEP) on patients receiving dual antiplatelet therapy (DAPT)

World Journal of Urology Nov 21, 2017

Sun J, et al. - Researchers coveted an examination of the safety and feasibility of Holmium laser enucleation of the prostate (HoLEP) in patients receiving dual antiplatelet therapy (DAPT). HoLEP exhibited similar results in patients receiving DAPT after coronary artery stunting and in patients receiving single antiplatelet (AP) therapy or non-AP therapy. It could present as a good option to the urologists for treating patients with symptomatic benign prostatic hyperplasia refractory to medical treatment.
Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen